Cargando…
Penfluridol overcomes paclitaxel resistance in metastatic breast cancer
Paclitaxel is a first line chemotherapeutic agent for the patients with metastatic breast cancer. But inherited or acquired resistance to paclitaxel leads to poor response rates in a majority of these patients. To identify mechanisms of paclitaxel resistance, we developed paclitaxel resistant breast...
Autores principales: | Gupta, Nehal, Gupta, Parul, Srivastava, Sanjay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434141/ https://www.ncbi.nlm.nih.gov/pubmed/30911062 http://dx.doi.org/10.1038/s41598-019-41632-0 |
Ejemplares similares
-
Low Dose of Penfluridol Inhibits VEGF-Induced Angiogenesis
por: Srivastava, Suyash, et al.
Publicado: (2020) -
Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis
por: Ranjan, Alok, et al.
Publicado: (2016) -
Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth
por: Ranjan, Alok, et al.
Publicado: (2017) -
Penfluridol suppresses glioblastoma tumor growth by Akt-mediated inhibition of GLI1
por: Ranjan, Alok, et al.
Publicado: (2017) -
Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis
por: Gupta, Nehal, et al.
Publicado: (2021)